AstraZeneca picks up an Amgen biologics plant; Soon-Shiong's diagnostics firm makes a buy;

@FierceBiotech: FierceBiotech radio on GSK's latest setback, Kyle Bass' 'truthful irrelevancy,' and Horizon's web presence. More | Follow @FierceBiotech

@JohnCFierce: Four years after a transatlantic slapdown, Merck KGaA will once again seek cladribine OK. Article | Follow @JohnCFierce

@DamianFierce: I hereby endorse this bold, disruptive approach to the language of innovation. More | Follow @DamianFierce

> AstraZeneca ($AZN) is buying a Colorado biologics manufacturing facility from Amgen ($AMGN) as it expands its portfolio of large-molecule therapies. More

> Patrick Soon-Shiong's diagnostics business, NantOmics, bought OncoPlex Diagnostics, a company focused on analyzing tumor cells. News

> Medical device giant Zimmer ($ZMH) is planning to lay off 279 employees when it closes its dental headquarters later this year. Story

Medical Device News

@FierceMedDev: ShiftLab's first device is nearing commercialization. Will it start a low-cost revolution? More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Robotic surgery aspirant receives $4M+ in equity financing. Article | Follow @VarunSaxena2

@EmilyWFierce: JAMA: Women face increased risk for second vaginal mesh surgery 10 years after implant. Article | Follow @EmilyWFierce

> Startup Velico nabs another $15.5M from BARDA for dried plasma tech. Story

> Nipro to buy partner, heart attack prediction imaging upstart Infraredx. Report

> WSJ: Feds to launch power morcellator probe aimed at FDA. Article

Pharma News

@FiercePharma: USDA, poultry producers warn MN officials to expect bird flu resurgenceFierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. Article | Follow @EricPFierce

@CarlyHFierce: This date last year, I saved a story on my computer as "GSK Woes." So basically, not much has changed. | Follow @CarlyHFierce

> Boehringer's Ofev, chasing a Roche rival, wins backing from NICE. Story

> AstraZeneca picks up discarded Amgen plant as part of its biologics expansion. Report

> AbbVie scores FDA approval for expanded Humira label. Article

Suggested Articles

Adimab spinout Adagio Therapeutics raised $50 million to develop antibodies that target SARS-CoV-2 and other coronaviruses.

Relay Therapeutics has pulled off a major upsized IPO worth $400 million to propel a pipeline of treatments aiming at previously undruggable targets.

The series C follows phase 1b data on the brain cancer treatment that persuaded existing investors including HP WILD to commit more cash.